|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0017262,
umls-concept:C0034802,
umls-concept:C0039286,
umls-concept:C0078058,
umls-concept:C0086418,
umls-concept:C0148199,
umls-concept:C0185117,
umls-concept:C0221099,
umls-concept:C0279752,
umls-concept:C0332281,
umls-concept:C0871261,
umls-concept:C1171892,
umls-concept:C1522673,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2005-7-21
|
|
pubmed:abstractText |
Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR2) are often coexpressed in breast cancer, and potentially affect cellular pathways and key proteins such as the estrogen receptor (ER) targeted by endocrine treatment. We therefore explored the association between adjuvant tamoxifen treatment in breast cancer and expression of VEGF-A and VEGFR2, as well as human epidermal growth factor receptor 2 (HER2), which represents a candidate gene product involved in tamoxifen resistance.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4695-704
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16034044-Adult,
pubmed-meshheading:16034044-Antineoplastic Agents, Hormonal,
pubmed-meshheading:16034044-Breast Neoplasms,
pubmed-meshheading:16034044-Chemotherapy, Adjuvant,
pubmed-meshheading:16034044-Female,
pubmed-meshheading:16034044-Humans,
pubmed-meshheading:16034044-Immunohistochemistry,
pubmed-meshheading:16034044-Middle Aged,
pubmed-meshheading:16034044-Premenopause,
pubmed-meshheading:16034044-Receptor, Epidermal Growth Factor,
pubmed-meshheading:16034044-Receptors, Estrogen,
pubmed-meshheading:16034044-Receptors, Progesterone,
pubmed-meshheading:16034044-Tamoxifen,
pubmed-meshheading:16034044-Treatment Outcome,
pubmed-meshheading:16034044-Vascular Endothelial Growth Factor A,
pubmed-meshheading:16034044-Vascular Endothelial Growth Factor Receptor-2
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
|
|
pubmed:affiliation |
Department of Surgery, Helsingborgs Lasarett, Helsingborg.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
